Tiziana Life Sciences Partners with KAIMRC for RRMS Combination Therapy Trial
Event summary
- Tiziana Life Sciences signed an MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating intranasal foralumab in combination with anti-CD20 therapy for RRMS patients.
- The trial aims to address neuroinflammation in patients responding poorly to anti-CD20 therapy alone.
- The MOU was signed on September 16, 2026, during the Riyadh Global Medical Biotechnology Summit.
- Tiziana's Phase 2 trial for non-active Secondary Progressive MS (na-SPMS) remains blinded with results expected in October 2026.
The big picture
Tiziana Life Sciences is expanding its clinical pipeline beyond its ongoing na-SPMS program by exploring combination therapies for RRMS. This strategic move aligns with broader industry trends toward personalized and combination therapies for complex neurodegenerative diseases. The partnership with KAIMRC and the Foundation for Neurologic Diseases underscores the growing global interest in collaborative approaches to address significant unmet medical needs in neuroimmunology.
What we're watching
- Clinical Trial Outcomes
- How the combination therapy trial results will impact Tiziana's strategic positioning in the neuroimmunology space.
- Regulatory Approvals
- The pace at which regulatory approvals for intranasal foralumab could accelerate given the new collaboration.
- Market Expansion
- Whether Tiziana can leverage this partnership to expand its market reach beyond its current focus on na-SPMS.
Related topics